The purification of monoclonal antibodies (mAbs) is commonly achieved by Protein A affinity chromatography, which can account for up to 25% of the overall process costs. Alternative, cost-effective capture steps are therefore valuable for industrial-scale manufacturing, where large quantities of a single mAb are produced. Here we present a method for the immobilization of a DsRed-based epitope ligand to a crosslinked agarose resin allowing the selective capture of the HIV-neutralizing antibody 2F5 from crude plant extracts without using Protein A. The linear epitope ELDKWA was first genetically fused to the fluorescent protein DsRed and the fusion protein was expressed in transgenic tobacco (Nicotiana tabacum) plants before purification by immobilized metal-ion affinity chromatography. Furthermore, a method based on activated cross-linked agarose was optimized for high ligand density, efficient coupling and low costs. The pH and buffer composition and the soluble ligand concentration were the most important parameters during the coupling procedure, which was improved using a design-of-experiments approach. The resulting affinity resin was tested for its ability to selectively bind the target mAb in a crude plant extract and the elution buffer was optimized for high mAb recovery, product activity and affinity resin stability. The method can easily be adapted to other antibodies with linear epitopes. The new resins allow gentler elution conditions than Protein A and could also reduce the costs of an initial capture step for mAb production.
Introduction
Biopharmaceutical products are important for the treatment of a broad spectrum of diseases in nearly every branch of medicine 1 . Monoclonal antibodies (mAbs) dominate the biopharmaceutical market, with worldwide sales expected to reach almost €110 billion in 2020 2 . The favored expression platform for mAbs are Chinese hamster ovary cell lines, which typically produce high mAb titers of up to 10 g•L -1 in the culture supernatant 3, 4 . However, the production of mAbs in mammalian cell cultures is expensive due to the high cost of the medium and the need for sterile fermentation 5 . Alternative expression platforms such as plants potentially offer a faster, simpler, less expensive and more scalable approach for industrial manufacturing 6, 7 .
In addition to the costs associated with mammalian cell cultures, the widespread use of Protein A affinity chromatography for product capture is a major cost driver for the industrial production of mAbs. Protein A is naturally found on the surface of Staphylococcus aureus cells and it binds to the fragment crystallizable (Fc) region of certain murine and human antibodies, thereby acting as a defense mechanism to evade the humoral immune system 8 . Protein A has become the industry gold standard for the capture of mAbs from cell culture supernatants and is also widely used by the research community because it is highly selective, typically achieving mAb purities of ~95% in a single step 8 . Unsurprisingly, sales of Protein A over the last two decades have closely mirrored the sales of mAbs 8 . Depending on the production scale, the costs of Protein A can correspond to more than 25% of the total process costs and thereby affect the market price of therapeutic mAbs, which can be up to €2,000 g -1 5, 9 . Therefore, alternative chromatography resins with a similar purification performance have the potential to substantially reduce production costs, making antibody-based therapies accessible for a larger number of patients 10, 11, 12 . Such alternatives may also circumvent the disadvantages of Protein A chromatography, including the harsh elution conditions at low pH (typically <3.5) that can potentially cause mAbs to undergo conformational changes that promote aggregation 13 . Importantly, Protein A is selective only for the Fc region of certain IgG subclasses, so non-functional molecules with truncated binding domains may co-purify with the intact product 5 , whereas mAb derivaties such as single-chain variable fragments do not bind to Protein A at all.
Here, we describe an alternative affinity chromatography resin for the capture of the HIV-neutralizing mAb 2F5 using its linear epitope ELDKWA (one letter amino acid code) 5, 14 . The purification strategy for mAb 2F5 was evaluated in terms of antibody purity, yield and ligand stability. In contrast to Protein A, which binds the Fc region, DFE bound to the complementarity-determining region of 2F5, ensuring the purification of molecules with an intact paratope. Our concept can easily be adapted to any mAb with a linear epitope or to other peptide-based affinity ligands which can be easily identified by microarray studies 16 . 
Protocol

Cultivate the Transgenic Tobacco Plants
NOTE:
The design of the DFE fusion protein and the generation of transgenic plants are described elsewhere 5, 17 .
1. Germinate the transgenic tobacco seedlings in soil. Irrigate the plants with a 1.0 g·L -1 fertilizer solution. Transfer the plants to single, 100 mm x 100 mm x 60 mm (length, width, height) pots when they grow to a diameter of ~0.04 m. 2. Cultivate the transgenic tobacco plants in a greenhouse with a 16-h photoperiod (25/22 °C light/dark temperature regime), with 70% relative humidity and automated fertilization with a 1.0 g·L -1 fertilizer solution for 15 min every hour.
3. After 7 weeks, harvest all leaves except the four cotyledon leaves at the base of the plant stem. Immediately process the harvested leaves as described below. . Mount an adjustable thermostat on the water bath for temperature control (steps 2.4 and 2.8).
Heat Precipitation of Host Cell Proteins
1. Place 150 g (wet mass) of blanched tobacco leaves (step 2.9) in the blender vessel and add 450 mL of extraction buffer (50 mM sodium phosphate, 500 mM sodium chloride, 10 mM sodium disulfite, pH 7.5). Close the blender cap tightly to prevent the spilling of plant material or buffer. 2. Homogenize the leaves for 3x for 30 s, with 30 s breaks between each pulse. Ensure that all leaves are homogenized and that none stick to the top of the blender vessel. If necessary, open the blender during the breaks and push down leaves that stick at the upper part of the vessel, using a clean silicone spoon. 3. After homogenization, take a 1.0 mL sample of the homogenate for subsequent analysis (step 7). 4. Collect the homogenate in a vessel of adequate size (e.g. if working with a total biomass of 1.0 kg, use a vessel with a capacity of at least a 5 L). Repeat steps 3.1 to 3.3 until all of the blanched biomass is homogenized. 5. Mount a bag filter into a filter mount and place another adequately sized vessel (see 3.4) beneath the assembly. Apply the homogenate to the bag filter at a rate of ~0.15 L min -1 . Take samples of the bag filtrate after each liter for subsequent analysis (step 7) and measure the turbidity of the bag filtrate pool as a 1:10 dilution in extraction buffer using a turbidimeter or similar device. 6. Further clarify the bag filtrate pool using 0.02 m 2 of a K700 (top) and KS50 (bottom) depth filter layer combination per liter of bag filtrate pool. 3. Equilibrate the column with 10 CV of equilibration buffer. Then load 50 CV of the clarified plant extract (from step 3.6) onto the conditioned column. 4. Wash the column with 10 CV of wash buffer. Elute the DFE fusion protein with 5 CV elution buffer and collect the product-containing fraction once the UV signals at 280 nm and 558 nm have increased to more than 5 mAU above the baseline. 5. Take a 0.2 mL sample from the elution fraction in order to measure the total soluble protein (TSP) concentration (step 7.1), DFE concentration (steps 7.2 and 7.3), and DFE purity (step 7.4). 6. Mount a column containing ~50 mL of cross-linked dextran resin on a chromatography system. Equilibrate the column with 5 CV of coupling buffer (200 mM HEPES, 500 mM sodium chloride, pH 8.5). Inject 10 mL of the DFE elution fraction (step 4.4) for buffer exchange and monitor the UV absorbance at 280 and 558 nm. 7. Collect the DFE-containing fraction once the UV signals at 280 nm and 558 nm have increased to more than 5 mAU above the baseline. Take a 0.2 mL sample and determine the TSP concentration, DFE concentration, and DFE purity (step 7). 8. Concentrate the purified DFE sample (from step 4.7) to 15 g L -1 using a centrifugal concentrator tube at 3,000 x g at 4 °C for 30 min in a centrifuge. Continue with the coupling reaction (step 5). NOTE: Store the DFE solution at 4 °C if the concentration or coupling steps cannot be carried out immediately. through fractions for all steps during the coupling reaction (step 5.7). 5. Open a sealed NHS-activated cross-linked agarose column and mount the syringe adapter at the column inlet. Prevent any air entering the column by applying a drop of buffer onto the adapter inlet before connecting it to the syringe. 6. Wash the column with 6 mL of ice-cold 1 mM hydrochloric acid (from step 5.4) at a flow rate of <1 mL min -1 and immediately proceed to step 5.7. 7. Inject 1.5 mL of DFE solution (step 5.2) using a 2 mL syringe at a flow rate of <1 mL min -1 and collect the flow-through fraction on a precision scale (step 5.4) for subsequent analysis (step 7). Seal the column at both ends and incubate for 15-45 min at 22 °C, depending on the DoE setup. 8. Inject 6 mL of deactivation solution followed by 6 mL of low-pH solution at a flow rate of <1 mL min -1 to remove non-covalently bound ligands from the resin. Then inject 6 mL of deactivation solution and incubate the column for 15 min. 9. Inject 6 mL of low-pH solution into the column, followed by 6 mL of deactivation solution. Then inject another 6 mL of low-pH solution into the column. 10. Inject 2 mL of storage solution into the column and store at 4 °C. 
Testing the Purification of mAbs from Clarified Plants Extracts
NOTE:
The magnesium chloride solution is prone to precipitation. Therefore, dissolve the magnesium chloride in ~700 mL of water. Separately dissolve the HEPES in 100 mL of water and adjust the pH to 8.0. Add the dissolved magnesium chloride solution to the HEPES solution and add water to a final volume of 1.0 L. Do not adjust the pH after dissolving the magnesium chloride because this will cause precipitation.
7. Analyze all samples taken during steps 6.4-6.6 using the Bradford method, lithium dodecylsulfate polyacrylamide gel electrophoresis (LDS-PAGE) and surface plasmon resonance (SPR) spectroscopy (step 7). Stain the gel for 1 h in staining solution on a shaker at 19 rpm. 6. Destain the gel for 1 h in water on a shaker at 19 rpm. Scan the gel using a film scanner.
Sample Analysis
Representative Results
Expression and purification of the affinity ligand
The fusion protein DFE was expressed in transgenic tobacco plants grown in a greenhouse. The yield was ~120 mg·kg -1 leaf mass with an average biomass of ~130 g per plant. The DFE purity was <5% of TSP in crude plant extracts before blanching but increased to ~40% after heat treatment at 70 °C for 1.5 min, which precipitated >97% of the host cell proteins. The blanching step was easily integrated into the harvesting and extraction routine (Figure 1 ) and took less than 2 h of extra time, including setting up the water bath. The overall recovery of DFE was 23.5 mg kg 1 with a purity of >90%. The steps responsible for product loss were blanching, depth filtration and IMAC, with specific losses of 40%, 27%
and 45%, respectively. The depth filter capacity was on average 135 ± 36 L m -2 (±SD, n=3) and thus in the upper range of values reported in the literature 21 . The DFE yield increased with plant age (Figure 2) .
Immobilization of the affinity ligand on NHS-activated chromatography columns
During initial coupling tests, we found that HEPES buffer (pH 8.3) increased the coupling efficiency to 89 ± 6% (±SD, n=3) compared to 78 ± 9% (±SD, n=3) for the bicarbonate buffer recommended by the manufacturer. Therefore, HEPES was used for all subsequent coupling experiments. A DoE approach was selected to optimize the coupling efficiency of DFE to NHS-activated cross-linked agarose resin. The absolute amount of DFE immobilized on the resin increased with the mass of DFE injected into the column and plateaued at ~15 g·L -1 whereas the coupling yield declined continuously as more DFE was injected (Figure 2) . The coupling yield was also >50% lower in an acidic buffer, indicating the need to screen for suitable coupling conditions for each ligand on a case-by-case basis. Ideal conditions in terms of coupling yield, absolute quantity of immobilized DFE and column costs were identified using the numerical optimization tool of the DoE software. The most desirable conditions (pH 9.0 and 7.0 mg of DFE per 1 mL of cross-linked agarose resin) were located on a large plateau and were therefore robust. The DFE molecules retained their red fluorescence even after coupling, and the color intensity corresponded to the total amount of immobilized DFE (Figure 2) . Therefore, column color can be used as a simple quality control parameter to estimate the coupling efficiency and column quality. The fluorescence also confirmed that DFE fusion protein assembled in the tetrameric state of native DsRed. 
Testing 2F5 isolation using the DFE affinity resin
The recombinant 2F5 antibody was transiently produced in Nicotiana benthamiana plants grown in a phytotron 5 . The capture of 2F5 from the crude plant extract was tested using affinity columns coupled with ~7.0 mg purified DFE (step 6). Elution from Protein A resins usually involves an acidic buffer (pH ~3.3) 13 . Therefore, we initially evaluated different low-pH elution buffers (pH 6.0-3.25) for the DFE columns. The elution of 2F5 was successful at pH values below 4.5 with the highest recovery of ~35% at pH 3.25. However, low-pH elution inactivated both the antibody (as confirmed by SPR spectrometry) and the DFE ligand (as indicated by the loss of color and the lower DBC, Figure 3) . The latter was anticipated given that native DsRed denatures at pH <4.0 22, 23 . To avoid product and ligand denaturation, we tested magnesium chloride as an alternative elution agent because it has previously been used to elute mAbs from other affinity resins 24 . A magnesium chloride concentration of 1.25 M was sufficient to elute 2F5 from the DFE affinity resin with a recovery of 105 ± 11% (±SD, n=3) and a purity of 97 ± 3% (±SD, n=3). This performance was comparable to Protein A resins 25, 26 . The equilibrium dissociation constant (K D ) of DFE-purified 2F5 antibody and the synthetic ligand Fuzeon was 791 pM whereas that of a Protein A-purified counterpart was 763 pM 5 . Furthermore, no substantial color loss was observed in the resin over a total of 25 bind-and-elute cycles. The DBC of the DFE affinity resin at 10% 2F5 breakthrough declined linearly over the course of 25 cycles to ~15% of the initial value (Figure 3 ). 
Discussion
Applications of the novel affinity resin
We have shown that custom affinity chromatography resins for the capture of mAbs can be manufactured by immobilizing a ligand containing a mAb-specific epitope to NHS-activated cross-linked agarose. To design such a resin, it was necessary to know the epitope sequence and to use a linear epitope. The resulting resins are advantageous for the capture of mAbs because they could potentially replace expensive Protein A affinity chromatography steps. The interaction between 2F5 and DFE in our case study was mediated by epitope-paratope binding, so our ligand should be more selective than Protein A, which binds to the Fc region of most murine and human IgGs. Because individual ligands are needed for each mAb, our method may initially seem suitable mainly for antibodies that are produced on a very large scale. However, by combining our approach with rapid plant-based transient protein expression, new affinity ligands can be prepared in less than 2 weeks 27 with minimal effort 28 . Hence, the method is also suitable for small-scale mAb purification.
Production and potential improvements of the affinity ligand
Plants offer a fast and safe production platform for affinity ligands 5, 29, 30 , such as the DFE fusion protein featured in our case study. Blanching the plant material greatly reduced the quantity of host cell proteins in a single step and was easily integrated into a standard clarification routine. However, the recovery of the ligand was low in the current setup, probably due to its moderate thermal stability and some non-specific binding to the filter layers, as reported for other products 31, 32, 33 . Engineering the carrier to increase its thermal stability may therefore help to improve the ligand yield in the future, as described for the malaria vaccine candidate CCT, the antitumor enzyme PpADI or a mesophilic β-glucosidase 34, 35, 36 . The same holds true for the depth filtration step, where protein engineering may help to reduce non-specific binding to the filter material 37 . The production costs for DFE and similar ligands could also be reduced by improving the overall efficiency of clarification using flocculants or filter additives 38, 39 .
When DsRed is used as a carrier, it forms a tetrameric complex. This is advantageous because it increases the number of epitopes per ligand, but it may also render the ligand more susceptible to disassembly or denaturation during affinity chromatography. A monomeric carrier protein such as mCherry may therefore be preferable, because it is stable at low pH 40 , and the inclusion of tandem repeats of the epitope would increase the avidity of the ligand and thus increase resin capacity 5, 26, 41 . For simple carrier-epitope proteins (i.e., those with no disulfide bonds or post-translational modifications) microbial production systems may reduce the manufacturing costs and make the ligands more competitive with Protein A. For example, green fluorescent protein has been expressed in bacterial cells with a yield of ~1 g·kg -1 biomass, which would significantly reduce ligand production costs 42 .
Regardless of the expression host, a purified affinity ligand was required during coupling to minimize the immobilization of host cell proteins or media components that can otherwise reduce resin selectivity and capacity. The inclusion of a poly-histidine tag for IMAC purification increased . However, the position of the fusion tag is important because it has the potential to sterically hinder epitope binding or to induce the cleavage of either the tag or the epitope from the carrier 45, 46 .
Immobilization of the affinity ligand on NHS-activated chromatography columns
Immobilization was carried out manually or using a chromatography system. The small buffer volumes per column seemed to favor manual handling (e.g., due to the minimal waste volumes). However, if multiple/larger columns are needed, the chromatography system makes the coupling conditions easier to control (e.g., regulated flow rates) and is therefore more likely to achieve reproducible results in terms of DBC. Our data suggest that the coupling buffer and pH have an important effect on the coupling efficiency and overall column costs. Screening factors that influence the coupling reaction and adjusting them for each carrier protein (or even for each carrier-ligand fusion) could therefore improve coupling efficiency and resin performance, and we recommend this approach.
Testing 2F5 isolation using the DFE affinity resin
Product yield and purity are important aspects of resin performance, and in the case of DFE we achieved a yield of 105 ± 11% (±SD, n=3) and a purity of 97 ± 3% (±SD, n=3), which is comparable with the performance of benchmark Protein A resins 25, 26 . Another key performance indicator for resins in general (and particularly for those based on affinity ligands) is the DBC at 10% product breakthrough, because this parameter affects the amount of resin required for a specific process and thus the costs. For the DFE ligand, the initial DBC was ~4 g·L -1 resin, which is ~13% of the corresponding value for Protein A under similar conditions (only 2 min contact time) 25 ,47 but about 15-fold higher compared to other custom affinity resins such as the anti-FSH-immunoaffinity ligand using the same residence time of 2 min 48 . The DBC of DFE declined to 15% of the starting value after 25 bind-and-elute cycles, whereas more than 50 cycles are required for the same loss of DBC in commercial Protein A resins 49 . However, it is important to note that our carrier has not yet been optimized to the same extent as Protein A, which has been comprehensively investigated and improved over the last four decades 8 .
Thus far we have improved the resin stability and product recovery by switching from a low-pH elution buffer to a high concentration of magnesium chloride (Figure 3) , as recommended in earlier studies 13 . The characteristic red color of the affinity ligand did not fade substantially during the 25 bind-and-elute cycles, so we speculate that endogenous plant proteases in the clarified plant extracts 31 may have truncated and thus inactivated the epitope of the ligand. Therefore, designing protease-resistant linkers to connect the carrier and epitope may help to maintain the initial DBC over an extended number of cycles. Given the rapid and simple expression and purification of the DFE ligand, its straightforward coupling to commercial chromatography resins, and its excellent product yield and purity, we believe that our method offers a suitable alternative to Protein A for the purification of mAbs and antibody derivatives which do not bind to Protein A, especially if improvements to the carrier and linker can improve the DBC and ligand stability. This assumption was supported by the small difference in the dissociation constant of DFEpurified and Protein A-purified 2F5 antibody 5 , indicating that our new affinity ligand allows the recovery of high-quality mAbs.
Benefits and current limitations of the method
Producing the affinity ligand as a genetic fusion with a carrier protein increases solubility in aqueous buffers and thus compatibility with typical ligand coupling conditions. In contrast, blank peptides derived from solid phase peptide synthesis may have limited solubility under these conditions due to their sequence 50 , which cannot be changed because it is dictated by the amino acid sequence of epitope recognized by the mAb to be purified. Others have therefore used an on-resin synthesis of peptide ligands 51 . The static binding capacity of the resulting resin was high (~80 g·L -1 ), but the process of resin preparation is lengthy, a dynamic binding capacity was not reported and the obtained purity and recovery were lower than in our approach. An additional advantage of a fusion protein ligand in laboratory scale is that the ligand and variants thereof can be rapidly produced, purified and tested with minimal effort in an easy-to-use high-through expression system 52 .
The two current limitations of the method presented here are the low dynamic binding capacity of 3 g·L -1 and its 90% reduction over the course of 25 bind-and-elute cycles 5 . These limitations can be addressed in the future by applying less stringent loading conditions and replacing the current DsRed carrier with an engineered, more stable variant respectively. For example, doubling the current contact time from 2 to 4 minutes has the potential to double the dynamic binding capacity as was shown for some Protein A resins 26 .
Troubleshooting
The following table highlights potential problems that can be encountered during this protocol and provides hints on how to solve them ( Table 1) 
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